Ovarian Neoplasm

46 women with platinum-sensitive, high-grade, BRCA1/2+ ovarian cancer received either olaparib monotherapy or olaparib/cediranib combination therapy. Median PFS was increased in combination therapy (… (full text at CIViC)

PMID 25218906 · Liu et al., 2014 · Open in CIViC

In a study of ovarian carcinomas, 81% of tumors with germline BRCA1/2 mutations were platinum sensitive, whereas only 60% of tumors with non-BRCA1/2 mutations were platinum sensitive (N=47; N=158; P=0… (full text at CIViC)

PMID 24240112 · Pennington et al., 2014 · Open in CIViC

In a study of ovarian carcinomas, 87% of tumors with somatic BRCA1/2 mutations were platinum sensitive, whereas only 60% of tumors with non-BRCA1/2 mutations were platinum sensitive (N=38; N=158; P=0.… (full text at CIViC)

PMID 24240112 · Pennington et al., 2014 · Open in CIViC

Combined meta-analysis of Study 10 (NCT01482715, phase I/II) and ARIEL2 (NCT01891344, phase II), both multi-centre, open-label, single-arm trials evaluating rucaparib in ovarian cancer with BRCA1 or B… (full text at CIViC)

PMID 28882436 · Oza et al., 2017 · Open in CIViC

Combined meta-analysis of Study 10 (NCT01482715, phase I/II) and ARIEL2 (NCT01891344, phase II), both multi-centre, open-label, single-arm trials evaluating rucaparib in ovarian cancer with BRCA1 or B… (full text at CIViC)

PMID 28882436 · Oza et al., 2017 · Open in CIViC

A phase 2 trial on patients with relapsed, platinum-sensitive high grade ovarian, fallopian tube or primary peritoneal carcinoma (ARIEL2 Part1, NCT01891344) was held to assess PARP inhibitor rucaparib… (full text at CIViC)

PMID 27908594 · Swisher et al., 2017 · Open in CIViC

A phase 2 trial on patients with relapsed, platinum-sensitive high grade ovarian, fallopian tube or primary peritoneal carcinoma (ARIEL2 Part1, NCT01891344) was held to assess PARP inhibitor rucaparib… (full text at CIViC)

PMID 27908594 · Swisher et al., 2017 · Open in CIViC

In a phase 2 study of 206 recurrent, platinum-sensitive, high-grade ovarian cancer patients, patients with germline or somatic BRCA1 or BRCA2 mutation (n=40) were associated with improved progression … (full text at CIViC)

PMID 27908594 · Swisher et al., 2017 · Open in CIViC

In a phase 2 study of 206 recurrent, platinum-sensitive, high-grade ovarian cancer patients, patients with germline or somatic BRCA1 or BRCA2 mutation (n=40) were associated with improved progression … (full text at CIViC)

PMID 27908594 · Swisher et al., 2017 · Open in CIViC

In a phase 2 study of 206 recurrent, platinum-sensitive, high-grade ovarian cancer patients, patients with germline or somatic BRCA1 or BRCA2 mutation (n=40) were associated with improved progression … (full text at CIViC)

PMID 27908594 · Swisher et al., 2017 · Open in CIViC

In a phase 2 study of 206 recurrent, platinum-sensitive, high-grade ovarian cancer patients, patients with germline or somatic BRCA1 or BRCA2 mutation (n=40) were associated with improved progression … (full text at CIViC)

PMID 27908594 · Swisher et al., 2017 · Open in CIViC

A panel of 40 ovarian cancer cell lines with varied mutation profiles was assayed for sensitivity to the cdk4/6 inhibitor palbociclib (PD0332991) via measurement of IC50 values for inhibition of proli… (full text at CIViC)

PMID 21278246 · Konecny et al., 2011 · Open in CIViC

In a retrospective study of 88 ovarian carcinomas, 18 had amplification of CCNE1. Those with amplification had worse overall and disease-free survival.

PMID 20336784 · Nakayama et al., 2010 · Open in CIViC

Small molecule inhibitors PHA-533533 and dinaciclib were used to treat CCNE1 amplified ovarian cancer cell lines. Inhibitors decreased pRb and increased apoptosis.

PMID 24004674 · Etemadmoghadam et al., 2013 · Open in CIViC

Four ovarian cancer cell lines with elevated CCNE1 expression were 40x more sensitive to Cdk2 inhibitor SNS-032 than four cell lines without CCNE1 overexpression. SNS-032 greatly prolonged the surviva… (full text at CIViC)

PMID 26204491 · Yang et al., 2015 · Open in CIViC

The effect of high CCNE1 expression on PD0332991 (palbociclib) sensitivity was observed in cell lines. One PD0332991 sensitive cell line, HEY, was engineered to constitutively express CCNE1 (HEY-CCNE… (full text at CIViC)

PMID 25557169 · Taylor-Harding et al., 2015 · Open in CIViC

High expression of PD-L1 and PD-1 were associated with a favorable prognosis in patients with high grade serous ovarian carcinoma (n = 215 cases).

PMID 26625204 · Darb-Esfahani et al., 2016 · Open in CIViC

In a clinical study including 59 stage III-IV ovarian cancer patients with peritoneal disseminated tumors, Kaplan-Meier analysis showed a significant association between CD44v6 high expression and wor… (full text at CIViC)

PMID 26250934 · Tjhay et al., 2015 · Open in CIViC

In an in vitro chemosensitivtiy assay, FACS-sorted CD44v6-positive cells show a significantly higher viability compared to CD44v6-negative cells when treated with 10nM of paclitaxel or 9 uM of cisplat… (full text at CIViC)

PMID 26250934 · Tjhay et al., 2015 · Open in CIViC

In models of high-grade serous ovarian cancer (HGS-OVCa), CDK12 attenuation was sufficient to confer sensitivity to PARP1/2 inhibition, suppression of DNA repair via homologous recombination, and redu… (full text at CIViC)

PMID 24240700 · Bajrami et al., 2014 · Open in CIViC

Preclinical study of the effects of PD-0332991 on proliferation, cell-cycle, apoptosis, and Rb phosphorylation in a panel of 40 human ovarian cancer cell lines. Concentration-dependent antiproliferati… (full text at CIViC)

PMID 21278246 · Konecny et al., 2011 · Open in CIViC

DICER1 mutations in the RNase IIIb domain were found in 29% of nonepithelial ovarian tumors (n=103) with high predominance in Sertoli-Lydig cell tumors (26/43; 60%). There were two mutations in D1709E… (full text at CIViC)

PMID 22187960 · Heravi-Moussavi et al., 2012 · Open in CIViC

DICER1 mutations in the RNase IIIb domain were found in 29% of nonepithelial ovarian tumors (n=103) with high predominance in Sertoli-Lydig cell tumors (26/43; 60%). There was one mutation in D1709G.

PMID 22187960 · Heravi-Moussavi et al., 2012 · Open in CIViC

DICER1 mutations in the RNase IIIb domain were found in 29% of nonepithelial ovarian tumors (n=103) with one mutation in a Juvenile ovarian granulosa-cell tumor (1/14; 7%). This individual had a somat… (full text at CIViC)

PMID 22187960 · Heravi-Moussavi et al., 2012 · Open in CIViC

In this exploratory study of Sertoli-Leydig cell tumors, DICER1 mutations were found in over half of the samples sequenced, but were not found to have any role in tumorigenesis, contrary to what was p… (full text at CIViC)

PMID 26428316 · Conlon et al., 2015 · Open in CIViC

DICER1 mutations in the RNase IIIb domain were found in 29% of nonepithelial ovarian tumors (n=103) with high predominance in Sertoli-Lydig cell tumors (26/43; 60%). There were ten mutations in D1709N… (full text at CIViC)

PMID 22187960 · Heravi-Moussavi et al., 2012 · Open in CIViC

DICER1 mutations in the RNase IIIb domain were found in 29% of nonepithelial ovarian tumors (n=103) with high predominance in Sertoli-Lydig cell tumors (26/43; 60%). There was one mutation in D1810H.

PMID 22187960 · Heravi-Moussavi et al., 2012 · Open in CIViC

DICER1 mutations in the RNase IIIb domain were found in 29% of nonepithelial ovarian tumors (n=103) with high predominance in Sertoli-Lydig cell tumors (26/43; 60%). There was one mutation in D1810N.

PMID 22187960 · Heravi-Moussavi et al., 2012 · Open in CIViC

DICER1 mutations in the RNase IIIb domain were found in 29% of nonepithelial ovarian tumors (n=103) with high predominance in Sertoli-Lydig cell tumors (26/43; 60%).Two Sertoli-Lydig cell tumors harbo… (full text at CIViC)

PMID 22187960 · Heravi-Moussavi et al., 2012 · Open in CIViC

DICER1 mutations in the RNase IIIb domain were found in 29% of nonepithelial ovarian tumors (n=103). Of the eight mature teratomas that were evaluated, one had a somatic mutation in D1810Y.

PMID 22187960 · Heravi-Moussavi et al., 2012 · Open in CIViC

Sanger sequencing identified DICER1 hotspot mutations in 20 of 32 (63%) ovarian Sertoli–Leydig cell tumors. These mutations were unrelated to tumor differentiation and mostly (16/20, 80%) were E1705K.… (full text at CIViC)

PMID 26428316 · Conlon et al., 2015 · Open in CIViC

DICER1 mutations in the RNase IIIb domain were found in 29% of nonepithelial ovarian tumors (n=103) with high predominance in Sertoli-Lydig cell tumors (26/43; 60%). There were five mutations in E1705… (full text at CIViC)

PMID 22187960 · Heravi-Moussavi et al., 2012 · Open in CIViC

DICER1 mutations in the RNase IIIb domain were found in 29% of nonepithelial ovarian tumors (n=103) with high predominance in Sertoli-Lydig cell tumors (26/43; 60%). There was one mutation in E1813G.

PMID 22187960 · Heravi-Moussavi et al., 2012 · Open in CIViC

DICER1 mutations in the RNase IIIb domain were found in 29% of nonepithelial ovarian tumors (n=103) with high predominance in Sertoli-Lydig cell tumors (26/43; 60%). There was one mutation in E1813K.

PMID 22187960 · Heravi-Moussavi et al., 2012 · Open in CIViC

E1813 residue has been described as a hotspot for somatic missense mutations in DICER1.

PMID 22187960 · Heravi-Moussavi et al., 2012 · Open in CIViC

In this exploratory study of Sertoli-Leydig cell tumors, DICER1 mutations were found in over half of the samples sequenced, but were not found to have any role in tumorigenesis, contrary to what was p… (full text at CIViC)

PMID 26428316 · Conlon et al., 2015 · Open in CIViC

DICER1 mutations in the RNase IIIb domain were found in 29% of nonepithelial ovarian tumors (n=103) with high predominance in Sertoli-Lydig cell tumors (26/43; 60%). There were two patients with E1813… (full text at CIViC)

PMID 22187960 · Heravi-Moussavi et al., 2012 · Open in CIViC

Sanger sequencing identified DICER1 hotspot mutations in 20 of 32 (63%) ovarian Sertoli–Leydig cell tumors. These mutations were unrelated to tumor differentiation and mostly (16/20, 80%) were E1705K.… (full text at CIViC)

PMID 26428316 · Conlon et al., 2015 · Open in CIViC

In an analysis of 107 patients enrolled in the International Ovarian and Testicular Stromal Tumor Registry, 5 had gynandroblastoma (14-32 yo). 4 of the 4 gynandroblastoms with material available for … (full text at CIViC)

PMID 29037807 · Schultz et al., 2017 · Open in CIViC

A sequencing analysis of the DICER1 RNase IIIb region in nonepithelial ovarian neoplasms revealed a striking concentration of somatic mutations at residues required for metal binding within the cataly… (full text at CIViC)

PMID 22187960 · Heravi-Moussavi et al., 2012 · Open in CIViC

Genomic analysis identified DICER1 RNase IIIb domain hotspot mutations in 3 of 16 cases of gynandroblastoma, leading the authors to suggest that DICER1 hotspot mutations are a key driver in a subset o… (full text at CIViC)

PMID 29660837 · Wang et al., 2018 · Open in CIViC

In an analysis of 107 patients enrolled in the International Ovarian and Testicular Stromal Tumor Registry, 5 had gynandroblastoma (14-32 yo). 4 of the 4 gynandroblastoms with material available for … (full text at CIViC)

PMID 29037807 · Schultz et al., 2017 · Open in CIViC

DNMT1 expression (mRNA expression from an independent study) correlated with sensitivity to decitabine (ρ, −0.443, Pearson regression analysis) in this preclinical study of 45 solid tumor cell lines. … (full text at CIViC)

PMID 25968887 · Stewart et al., 2015 · Open in CIViC

The functional variant rs61764370 in the KRAS gene 3' UTR (KRAS-variant) was found to be correlated with platinum-based chemotherapy resistance in patients with Epithelial Ovarian Cancer (EOC). 291 EO… (full text at CIViC)

PMID 22139083 · Ratner et al., 2012 · Open in CIViC

A variant of EGFR with exon 4 deletion (de4 EGFR) enhanced the invasiveness and cisplatin resistance of epithelial ovarian cancer cell lines (SKOV3, CAOV3, ES2) in vitro when compared with wild-type E… (full text at CIViC)

PMID 23764753 · Zhang et al., 2013 · Open in CIViC